Related Experiment Video
Updated: Jun 18, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
[Pulmonary fibrosis]
A Prasse1, J U Holle, J Müller-Quernheim
1Abteilung für Pneumologie, Universitätsklinikum Freiburg, Killianstrasse 5, 79106 Freiburg, Deutschland. antje.prasse@uniklinik-freiburg.de
Abstract:
Many, different diseases can result in pulmonary fibrosis and its prevalence is continuously increasing. Pulmonary fibrosis is defined by a diffuse accumulation of connective tissue in the interstitial space resulting in destruction of lung parenchyma. Older individuals are more often affected by this disease than younger. Approximately one half of all patients with pulmonary fibrosis suffer from rheumatic diseases. The classification of pulmonary fibrosis was revised 1998. Now 6 different types of interstitial pneumonia according to 6 different pathologic patterns are newly defined. Still, there is no efficient treatment known, which resolves fibrotic lung remodeling. However, immunosuppressive treatment strategies are established in pulmonary fibrosis evoked by inflammatory processes.
Related Concept Videos
Chronic Obstructive Pulmonary Disease II: Emphysema
Other Pulmonary Disorders
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
